{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:30:12Z","timestamp":1778808612437,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.clbc.2018.04.009","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T09:57:06Z","timestamp":1524131826000},"page":"e1149-e1163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor"],"prefix":"10.1016","volume":"18","author":[{"given":"Zhe-Yu","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huawu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengjia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze-Ming","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2018.04.009_bib1","first-page":"271","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2018.04.009_bib2","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(11)61351-2","article-title":"Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis","volume":"378","author":"Forouzanfar","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2018.04.009_bib3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10549-013-2500-7","article-title":"Trends in breast cancer incidence and mortality in the United States: implications for prevention","volume":"138","author":"Toriola","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2018.04.009_bib4","first-page":"31","article-title":"Breast cancer statistics, 2015: convergence of incidence rates between black and white women","volume":"66","author":"DeSantis","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2018.04.009_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2018.04.009_bib6","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0140-6736(08)61255-6","article-title":"Declining breast cancer incidence and decreased HRT use","volume":"372","author":"Kumle","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2018.04.009_bib7","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJMsr070105","article-title":"The decrease in breast-cancer incidence in 2003 in the United States","volume":"356","author":"Ravdin","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2018.04.009_bib8","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa050518","article-title":"Effect of screening and adjuvant therapy on mortality from breast cancer","volume":"353","author":"Berry","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2018.04.009_bib9","first-page":"359","article-title":"The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: results and reflections","volume":"66","author":"Byers","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2018.04.009_bib10","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.1998.16.3.1008","article-title":"Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant","volume":"16","author":"Laughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2018.04.009_bib11","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/jnci\/91.19.1654","article-title":"Tamoxifen therapy for breast cancer and endometrial cancer risk","volume":"91","author":"Bernstein","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2018.04.009_bib12","first-page":"151","article-title":"Endometrial cancer incidence in breast cancer patients correlating with age and duration of tamoxifen use: a population based study","volume":"5","author":"Chen","year":"2014","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.clbc.2018.04.009_bib13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/jnci\/87.9.645","article-title":"Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group","volume":"87","author":"Rutqvist","year":"1995","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2018.04.009_bib14","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/JME-14-0252","article-title":"Progesterone action in breast, uterine, and ovarian cancers","volume":"54","author":"Diep","year":"2015","journal-title":"J\u00a0Mol Endocrinol"},{"key":"10.1016\/j.clbc.2018.04.009_bib15","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis Consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2018.04.009_bib16","first-page":"851","article-title":"[Expression of estrogen receptor and progesterone receptor in colorectal cancer: a quantitative study]","volume":"23","author":"Zhou","year":"2004","journal-title":"Ai Zheng"},{"key":"10.1016\/j.clbc.2018.04.009_bib17","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/carcin\/bgq009","article-title":"Hormone therapy, DNA methylation and colon cancer","volume":"31","author":"Wu","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.clbc.2018.04.009_bib18","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/jcp.2006.038281","article-title":"HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer","volume":"60","author":"Al-Kuraya","year":"2007","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clbc.2018.04.009_bib19","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3390\/ijms17122040","article-title":"HER2 analysis in sporadic thyroid cancer of follicular cell origin","volume":"17","author":"Ruggeri","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clbc.2018.04.009_bib20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4048\/jbc.2015.18.4.378","article-title":"Risk of second primary malignancy in breast cancer survivors: a nested population-based case-control study","volume":"18","author":"Marcheselli","year":"2015","journal-title":"J\u00a0Breast Cancer"},{"key":"10.1016\/j.clbc.2018.04.009_bib21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1056\/NEJMicm1516482","article-title":"Radiation-induced angiosarcoma after breast-cancer treatment","volume":"376","author":"Plichta","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2018.04.009_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jnci\/djj001","article-title":"Cancer survivorship\u2014genetic susceptibility and second primary cancers: research strategies and recommendations","volume":"98","author":"Travis","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2018.04.009_bib23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(88)92675-X","article-title":"Tamoxifen as risk factor for carcinoma of corpus uteri","volume":"2","author":"Hardell","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2018.04.009_bib24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/jamaoncol.2015.4265","article-title":"Familial risk in patients with carcinoma of unknown primary","volume":"2","author":"Samadder","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2018.04.009_bib25","first-page":"3069","article-title":"Aromatase in colon carcinoma","volume":"32","author":"Sato","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clbc.2018.04.009_bib26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1309\/5MHB-K6XX-QV50-PCJQ","article-title":"Estrogen and progesterone receptors in colon tumors","volume":"113","author":"Slattery","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clbc.2018.04.009_bib27","first-page":"3155","article-title":"Estrogen and progesterone receptors in gastric and colorectal cancer","volume":"46","author":"Oshima","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.clbc.2018.04.009_bib28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/jnci\/87.7.517","article-title":"Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women","volume":"87","author":"Calle","year":"1995","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2018.04.009_bib29","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1677\/joe.0.1740369","article-title":"Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta","volume":"174","author":"Qiu","year":"2002","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.clbc.2018.04.009_bib30","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/bjc.2012.323","article-title":"Expression of oestrogen receptor beta and prognosis of colorectal cancer","volume":"107","author":"Rudolph","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2018.04.009_bib31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4048\/jbc.2012.15.3.283","article-title":"Associations between BRCA mutations in high-risk breast cancer patients and familial cancers other than breast or ovary","volume":"15","author":"Noh","year":"2012","journal-title":"J\u00a0Breast Cancer"},{"key":"10.1016\/j.clbc.2018.04.009_bib32","doi-asserted-by":"crossref","unstructured":"Yadav S, Ladkany R, Yadav D, et\u00a0al. Impact of BRCA mutation status on survival of women with triple-negative breast cancer, Clin Breast Cancer 2017. https:\/\/doi.org\/10.1016\/j.cibc.2017.12.014, [Epub ahead of print].","DOI":"10.1016\/j.clbc.2017.12.014"},{"key":"10.1016\/j.clbc.2018.04.009_bib33","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/carcin\/bgi136","article-title":"BRCA1 and BRCA2 as ovarian cancer susceptibility genes","volume":"26","author":"Sowter","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.clbc.2018.04.009_bib34","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2018.04.009_bib35","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1245\/s10434-013-2892-y","article-title":"The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States","volume":"20","author":"Aschebrook-Kilfoy","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2018.04.009_bib36","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ijc.29426","article-title":"CHEK2 mutations and the risk of papillary thyroid cancer","volume":"137","author":"Siolek","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clbc.2018.04.009_bib37","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1177\/000313480306901216","article-title":"HER2 expression in thyroid tumors","volume":"69","author":"Mondi","year":"2003","journal-title":"Am Surg"},{"key":"10.1016\/j.clbc.2018.04.009_bib38","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/gtmb.2009.0068","article-title":"Association of EGFR and HER2 polymorphisms with\u00a0risk and clinical features of thyroid cancer","volume":"13","author":"Rebai","year":"2009","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.clbc.2018.04.009_bib39","first-page":"387","article-title":"Use of breast reconstruction after mastectomy following the Women's Health and Cancer Rights Act","volume":"295","author":"Alderman","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2018.04.009_bib40","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/cncr.20529","article-title":"The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer","volume":"101","author":"Tseng","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2018.04.009_bib41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/bjc.2016.108","article-title":"A\u00a0population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction","volume":"115","author":"Warschkow","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2018.04.009_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1746-1596-4-11","article-title":"Primary anaplastic large cell lymphoma of the breast arising in reconstruction mammoplasty capsule of saline filled breast implant after radical mastectomy for breast cancer: an unusual case presentation","volume":"4","author":"Bishara","year":"2009","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.clbc.2018.04.009_bib43","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1158\/1078-0432.CCR-12-0101","article-title":"Survival signals and targets for therapy in breast implant-associated ALK\u2014anaplastic large cell lymphoma","volume":"18","author":"Lechner","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2018.04.009_bib44","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/sj.leu.2404709","article-title":"Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies","volume":"21","author":"Guillem","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clbc.2018.04.009_bib45","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1684\/bdc.2009.0958","article-title":"[High risk of cardiac dysfunction after treatment of secondary acute myeloid leukemia following chemotherapy and radiotherapy for breast cancer]","volume":"97","author":"Willems","year":"2010","journal-title":"Bull Cancer"},{"key":"10.1016\/j.clbc.2018.04.009_bib46","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2001.19.4.1231","article-title":"Secondary leukemia after adjuvant chemotherapy for breast cancer","volume":"19","author":"Ghalie","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2018.04.009_bib47","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/15384047.2016.1139233","article-title":"How breast cancer chemotherapy increases the risk of leukemia: thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy","volume":"17","author":"Zhang","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clbc.2018.04.009_bib48","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1002\/cncr.24462","article-title":"Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival","volume":"115","author":"Mery","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2018.04.009_bib49","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2340\/00015555-0841","article-title":"Synchronous angiosarcoma, melanoma and morphea of the breast skin 14 years after radiotherapy for mammary carcinoma","volume":"90","author":"de Giorgi","year":"2010","journal-title":"Acta Derm Venereol"}],"updated-by":[{"DOI":"10.1016\/j.clbc.2018.10.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000}}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091830048X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091830048X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:19:11Z","timestamp":1761513551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682091830048X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S152682091830048X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2018.04.009","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2018.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}